ChiCTR2000037535 版本V1.0 版本创建时间2020/10/26 01:02:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000037535 

最近更新日期:

Date of Last Refreshed on:

2020-08-28 23:09:36 

注册时间:

Date of Registration:

2020-08-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

先天性肾脏及尿路畸形的出生缺陷预警及早期精准诊断

Public title:

Prediction of Renal Parenchymal Damage of CAKUT

注册题目简写:

English Acronym:

研究课题的正式科学名称:

先天性肾脏及尿路畸形的出生缺陷预警及早期精准诊断

Scientific title:

Protocol for a Cohort Diagnostic Accuracy Study to Develop Prediction of Renal Parenchymal Damage and to Evaluate Accuracy of Renal Function in Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李雅琦 

研究负责人:

饶佳 

Applicant:

Yaqi Li 

Study leader:

Jia Rao 

申请注册联系人电话:

Applicant telephone:

18956006768

研究负责人电话:

Study leader's telephone:

021-64932881

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yakee9717@163.com

研究负责人电子邮件:

Study leader's E-mail:

jiarao@fudan.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市闵行区万源路399号

研究负责人通讯地址:

上海市闵行区万源路399号

Applicant address:

399 Wanyuan Road, Minhang District, Shanghai, China

Study leader's address:

399 Wanyuan Road, Minhang District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属儿科医院

Applicant's institution:

Children's Hospital of Fudan University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

【2020】363

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属儿科医院伦理委员会

Name of the ethic committee:

Institutional Review Board of Children's Hospital of Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-08-27 00:00:00

伦理委员会联系人:

钱莉玲

Contact Name of the ethic committee:

Liling Qian

伦理委员会联系地址:

上海市闵行区万源路399号

Contact Address of the ethic committee:

399 Wanyuan Road, Minhang District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

021-64931913

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属儿科医院

Primary sponsor:

Children's Hospital of Fudan University

研究实施负责(组长)单位地址:

上海市闵行区万源路399号

Primary sponsor's address:

399 Wanyuan Road, Minhang District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

闵行区

Country:

China

Province:

Shanghai

City:

Minhang District

单位(医院):

复旦大学附属儿科医院

具体地址:

上海市闵行区万源路399号

Institution
hospital:

Children's Hospital of Fudan University

Address:

399 Wanyuan Road, Minhang District

经费或物资来源:

复旦大学附属儿科医院

Source(s) of funding:

Children's Hospital of Fudan University

Target disease:

Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1、确立CAKUT患儿影像学表型-基因型-尿液分子表型谱的迭加分析预测模型,形成CAKUT肾脏发育缺陷和功能损害的精准预警方案。 2、全面评估CAKUT孕前-孕期-生后的高危因素,提出CAKUT高危新生儿的早期诊断优化策略  

Objectives of Study:

To establish the prediction of the renal damage and renal development deficiency in congenital anomalies of kidney and urinary tract (CAKUT), a diagnostic accuracy study on MRI-DWI combined with urinary microprotein detection is to carried out comparing with DMSA scan as the golden standard for renal damage.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

CAKUT临床及遗传分子学诊断确立患儿:
1)肾实质发育缺陷或异位,包括
①肾缺如(renal agenesis,RA)超声诊断单侧肾脏的缺失。
②肾发育不全(renal hypoplasia,RH)/肾发育不良(renal dysplasia,RD)临床上RH常定义为肾脏体积小于同龄平均值两个标准差,或肾脏总体积小于同龄正常值50%以上;RD是指肾脏存在未分化或化生的组织成分,伴或不伴肾脏体积缩小,诊断依据包括超声发现皮髓质回声增强,及多囊肾发育不良(multicystic dysplastic kidney,MCDK),同时通过同位素肾脏功能显象(DMSA或DTPA)诊断单侧或双侧的肾脏功能缺陷。
2)肾小管发育异常:
①常染色体隐性遗传/常染色显性遗传多囊肾(Polycystic kidney disease,PDK, ADPKD/ARPKD)诊断主要依赖于影像学诊断;ADPKD阳性家族史的患者单侧或双侧肾囊肿超过3个即可诊断ADPKD,如无阳性家族史双侧肾脏弥漫增大伴多个囊肿,需临床考虑PKD,建议进行相关基因筛查。
②单纯性肾囊肿 :超声或其他影像学检查发现单一肾囊肿;
③髓质囊性病/纤毛病(Nephronophthisis,NPHP):超声发现肾脏回声增强或皮髓质交界不清,伴或不伴尿检异常或其他肾外系统累及,需考虑基因检测排查NPHP;遗传分子学诊断是NPHP诊断的主要诊断依据。
④肾钙盐沉着症或泌尿道结石:诊断有赖于超声诊断肾钙质沉着症或泌尿道结石,其原发疾病的诊断需进一步进行血清及尿液电解质及代谢物相关检查。
3)输尿管肾盂及膀胱异常:
①双集合系统:重复肾或重复肾盂/输尿管有赖于超声、磁共振(MRI)影像学诊断。
②泌尿道梗阻:包括输尿管肾盂连接处梗阻、输尿管膀胱连接处梗阻或关闭不全。梗阻部分和程度的诊断有赖于磁共振水成像(MRU)及同位素肾动态现象(DTPA) ③ 膀胱输尿管反流:诊断有赖于逆行膀胱尿路造影(VCUG)检查。
4)尿道发育异常:
①尿道缺如/闭锁/异位开口:诊断有赖于查体及VCUG检查。
②后尿道瓣膜:超声发现严重的肾积水,诊断有赖于VCUG检查。
备注:CAKUT诊断金标准的判定,由2名以上经过专业培训的影像学医师进行判读,同时经儿科医院肾脏及泌尿系疾病诊治中心的专业诊治医师进行最终疾病诊断。

Inclusion criteria

Patient that was diagnosed clinically and genetically as:
1.Renal parenchymal aplasia or ectopia, including simple renal aplasia,Multicystic Dysplastic Kidney, kidney tubules dysplasia, and hereditary cystic kidney. ①disease renal agenesis (RA): With ultrasound diagnosis of unilateral renal absence.②Renal hypoplasia (RH)/renal dysplasia (RD) is usually defined as renal volume less than two standard deviations of the average of the same age, or renal total volume less than 50% of the normal value of the same age. RD refers to the presence of undifferentiated or not metaplastic tissue in the kidney, with or without renal volume reduction. Diagnosis is based on the ultrasonic findings of multicystic dysplastic kidney (MCDK) and the diagnosis of unilateral or bilateral renal functional defects by means of isotopic renal functional imaging (DMSA or DTPA);
2.Kidney tubular dysplasia: ①the diagnosis of polycystic kidney disease(ADPKD/ARPKD) is mainly dependent on imaging; Patients with a family history of ADPKD can be diagnosed with more than 3 renal cysts on either side. those who with bilateral renal diffuse enlargement with multiple cysts should be clinically considered with PKD even without family history of ADPKD, and relevant gene screening is recommended.②Simple renal cyst: single renal cyst was found by ultrasound or other imaging examination;③Nephronophthisis, NPHP: ultrasonography showed enhanced renal echo or unclear boundary between cortex and medulla, with or without genetic diagnosis or involvement of other system, gene sequence should be considered. Genetic molecular diagnosis is the main diagnostic basis of NPHP diagnosis.④nephrocalcinosis and urinary calculi: the diagnosis depends on the ultrasound diagnosis and the examinations of serum and urine electrolyte and metabolite should be performed to further diagnose the primary disease.
3.Abnormalities of Ureter renal pelvis and/or bladder: ① Dual collection system: Reduplication of kidney or renal pelvis/ureter depends on ultrasound, magnetic resonance imaging (MRI) diagnosis. ② Urinary obstruction: Including ureteropelvic junction obstruction, ureterovesical junction obstruction or insufficiency. The diagnosis of obstruction depends on magnetic resonance urography (MRU) and isotopic dynamic renal imaging(DTPA) ③ vesicoureteral reflux: The diagnosis depends on voiding cysternography (VCUG).
4.Urinary tract anomalies: ① Urethral absence/urethra atresia/ectopic orifice: Diagnosis depends on physical examination and VCUG examination. ② Posterior urethral valve: Severe hydronephrosis can be found by ultrasound, and the diagnosis depends on VCUG examination.

排除标准:

1)项目入组3月内不同病因导致肾功能衰竭无法留取到尿液标本的患者;
2)研究者认为不适合入组的情况

Exclusion criteria:

1.Patient with renal failure due to different causes but without urine specimen;
2.Other conditions that the researcher considers not suitable for inclusion

研究实施时间:

Study execute time:

From 2020-12-01 00:00:00 To 2024-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-12-01 00:00:00 To 2022-12-01 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

放射性核素肾静态扫描:99m锝二巯基丁二酸(99m Tc-DMSA)静脉注射99mTc-DMSA 5mCi,1小时后行肾区前、后位平面显像。患儿在进行检查当日需在近心端静脉穿刺留置针,5岁以下儿童进行检查前需于复旦大学附属儿科医院镇静中心进行口服水合氯醛等镇静处理。图像解读:正常肾扫描图,呈椭圆形,轮廓清晰,边缘整齐,除肾门区分布稀疏外,其余分布均匀,两侧对比,放射性分布无明显差别。异常指示包括肾大小异常、放射性分配较稀疏,且不均匀,双侧分肾功能比例相差>10%,轮廓缺损肾疤痕形成。图像解读由2名核医学高年资医师在不知道尿液检测或肾功能评价其他检查结果的情况下共同对图像进行分析观察。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

肾脏MRI/DWI检查合并尿液磁珠富集多肽检测:MR弥散加权成像(diffusion weighted imaging, DWI):所有扫描均使用Siemens公司生产的Magnetom Verio 3.0T磁共振成像系统,2名腹部影像高年资医师在不知道尿液检测或肾功能评价其他检查结果的情况下共同对图像进行分析观察,判断结果不一致的经讨论后达成一致诊断结论。尿液磁珠富集多肽检测方案:CAKUT诊断确立3月内采集首份样本,尿样标本采集可选取多次尿样标本,采集量要求50ml-100ml,同时检测尿比重>1.010。尿样标本采集当日离心后,尿沉渣尿道上皮脱离细胞裂解蛋白应用纳米磁珠富集技术处理。

Index test:

Combined diagnosis of renal parenchymal damage includes MRI-DWI scan and the urinary biomarkers detection.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

CAKUT临床及遗传分子学诊断确立患儿。

例数:

Sample size:

960

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Pediatric children diagnosed of CAKUT clinically or genetically.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

NA

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

闵行区 

Country:

China 

Province:

Shanghai 

City:

Minhang Dstrict 

单位(医院):

复旦大学附属儿科医院 

单位级别:

三级甲等 

Institution
hospital:

Children's Hospital of Fudan University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

磁共振弥散加权成像影像

指标类型:

主要指标

Outcome:

MRI-DWI images

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿液多肽

指标类型:

主要指标

Outcome:

urinary polypeptide

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

放射性核素肾静态扫描影像

指标类型:

主要指标

Outcome:

dimercaptosuccinic acid (DMSA) scan images

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

致病基因

指标类型:

次要指标

Outcome:

disease gene

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由统计人员运用SPSS统计软件,采用随机数字表法生成随机方案。

Randomization Procedure (please state who generates the random number sequence and by what method):

The statistician uses SPSS, a statistical software, and the random number table method to generate the random scheme.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

共享至国家儿童遗传性肾脏病数据库平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Upload to Chinese Children Genetic Kidney Disease Database. Website: www.ccgkdd.com.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表采集,Excel和SPSS管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF, Excel and SPSS

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-08-28 23:09:36